The insulinotropic effect of DPP-4 inhibitors explains the phenomenon that this class increasingly is replacing the use of sulfonylureas as insulin releasing agents
While this study focused on opioids, it pointed toward a broader relationship between GLP-1 drugs and substance use risk
Annualized changes were compared between groups using analysis of covariance (ANCOVA) with adjustment for baseline clock value, chronological age, sex, BMI, high-sensitivity C-reactive protein (hsCRP), and soluble cluster of differentiation 163 (sCD163)
Although no study has directly compared the effects of repaglinide and mitiglinide, significant reductions in HbA1c and fasting plasma glucose were observed in a report of patients who switched from mitiglinide (30 mg/day) to repaglinide (1.5 mg/day) [15], and it was presumed that the hypoglycemic effect of repaglinide (1.5 mg/day) was stronger than that of mitiglinide (30 mg/day)
Colletti, A., & Cicero, A
Of the patients who took semaglutide and then developed NAION, those aged 40 to 64 (HR=3.31), who were female (HR=3.24), who were white (HR=2.34) or who had hypertension (HR=2.42) were more likely to be affected
